Becton, Dickinson and Company (NYSE:BDX) Hits New 1-Year High – Here’s What Happened

Posted by Brenda Bartman on Nov 6th, 2026

Becton, Dickinson and Company (NYSE:BDX – Get Free Report) reached a new 52-week high during mid-day trading on Wednesday. The company traded as high as $205.98 and last traded at $204.7940, with a volume of 113,926 shares traded. The stock had previously closed at $198.17.

Becton, Dickinson and Company News Summary

Here are the key news stories impacting Becton, Dickinson and Company this week:

Positive Sentiment: BD beat estimates for the quarter ended September 2026, with adjusted EPS of $4.15 versus roughly $4.06–$4.07 expected and revenue of $5.3 billion versus $5.11 billion expected. Revenue rose 5.4% year over year. BD fiscal 2026 results
Positive Sentiment: Cash from continuing operations increased 30% for fiscal 2026 to $3.6 billion, while free cash flow rose 42.5% to $2.9 billion, supporting financial flexibility. BD fiscal 2026 results
Positive Sentiment: BD authorized repurchases of up to 10 million shares—about 3.6% of shares outstanding—and raised its quarterly dividend 1% to $1.06, extending its annual dividend-increase streak to 55 years. Dividend and buyback announcement
Positive Sentiment: Evercore ISI raised its price target to $230 from $210, signaling improved analyst valuation expectations. Evercore ISI price-target update
Negative Sentiment: The fiscal 2027 outlook was the key drawback: reports characterized the revenue-growth forecast as subdued and guidance as around, or slightly below, expectations. That cautious outlook prompted a negative stock reaction despite the quarterly beat. BDX outlook coverage

Analyst Ratings Changes

BDX has been the topic of a number of research analyst reports. Royal Bank Of Canada boosted their price objective on shares of Becton, Dickinson and Company from $180.00 to $190.00 and gave the company a “sector perform” rating in a research report on Thursday, August 13th. Jefferies Financial Group reiterated a “buy” rating and issued a $242.00 target price on shares of Becton, Dickinson and Company in a research report on Thursday. Weiss Ratings raised shares of Becton, Dickinson and Company from a “hold (c-)” rating to a “hold (c)” rating in a research note on Wednesday. Wells Fargo & Company boosted their price target on shares of Becton, Dickinson and Company from $161.00 to $170.00 and gave the company an “equal weight” rating in a report on Friday, August 7th. Finally, Piper Sandler upped their price target on shares of Becton, Dickinson and Company from $161.00 to $175.00 and gave the stock a “neutral” rating in a research note on Friday, August 7th. One research analyst has rated the stock with a Strong Buy rating, eight have given a Buy rating, eight have given a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, Becton, Dickinson and Company currently has an average rating of “Moderate Buy” and a consensus target price of $187.20.

View Our Latest Stock Report on BDX

Becton, Dickinson and Company Trading Up 1.8%

The firm has a market capitalization of $58.70 billion, a price-to-earnings ratio of 64.17, a price-to-earnings-growth ratio of 14.10 and a beta of 0.22. The company has a fifty day moving average price of $187.69 and a 200-day moving average price of $170.23. The company has a current ratio of 0.87, a quick ratio of 0.51 and a debt-to-equity ratio of 0.55.

Becton, Dickinson and Company (NYSE:BDX – Get Free Report) last released its quarterly earnings data on Thursday, November 5th. The medical instruments supplier reported $4.15 EPS for the quarter, topping analysts’ consensus estimates of $4.07 by $0.08. The firm had revenue of $5.27 billion for the quarter, compared to the consensus estimate of $5.11 billion. Becton, Dickinson and Company had a return on equity of 14.79% and a net margin of 4.52%. The firm’s revenue was up 5.4% on a year-over-year basis. During the same quarter in the prior year, the company posted $3.96 earnings per share. On average, equities research analysts predict that Becton, Dickinson and Company will post 12.67 EPS for the current year.

Becton, Dickinson and Company Increases Dividend

The firm also recently declared a quarterly dividend, which will be paid on Thursday, December 31st. Stockholders of record on Thursday, December 10th will be paid a dividend of $1.06 per share. This is a positive change from Becton, Dickinson and Company’s previous quarterly dividend of $1.05. The ex-dividend date is Thursday, December 10th. This represents a $4.24 annualized dividend and a dividend yield of 2.0%. Becton, Dickinson and Company’s dividend payout ratio (DPR) is currently 126.51%.

Becton, Dickinson and Company declared that its board has authorized a share repurchase plan on Thursday, November 5th that allows the company to buy back 10,000,000 outstanding shares. This buyback authorization allows the medical instruments supplier to purchase up to 3.6% of its stock through open market purchases. Stock buyback plans are often a sign that the company’s board of directors believes its shares are undervalued.

Insider Activity at Becton, Dickinson and Company

In related news, CEO Thomas Polen, Jr. sold 4,152 shares of Becton, Dickinson and Company stock in a transaction on Thursday, August 13th. The shares were sold at an average price of $185.00, for a total value of $768,120.00. Following the completion of the sale, the chief executive officer owned 110,163 shares of the company’s stock, valued at approximately $20,380,155. The trade was a 3.63% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Michael Feld sold 165 shares of the company’s stock in a transaction on Wednesday, August 26th. The stock was sold at an average price of $188.49, for a total transaction of $31,100.85. Following the completion of the sale, the executive vice president owned 19,720 shares of the company’s stock, valued at $3,717,022.80. This represents a 0.83% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last 90 days, insiders sold 6,907 shares of company stock valued at $1,269,128. Insiders own 0.40% of the company’s stock.

Institutional Inflows and Outflows

A number of hedge funds have recently made changes to their positions in the stock. BlackRock Inc. bought a new stake in shares of Becton, Dickinson and Company during the second quarter worth $3,721,533,000. State Street Corp raised its holdings in shares of Becton, Dickinson and Company by 8.5% in the second quarter. State Street Corp now owns 15,000,064 shares of the medical instruments supplier’s stock valued at $2,269,960,000 after buying an additional 1,177,256 shares during the last quarter. First Eagle Investment Management LLC raised its holdings in shares of Becton, Dickinson and Company by 15.8% in the second quarter. First Eagle Investment Management LLC now owns 13,815,335 shares of the medical instruments supplier’s stock valued at $2,090,675,000 after buying an additional 1,887,224 shares during the last quarter. Bank of America Corp DE acquired a new position in Becton, Dickinson and Company during the 2nd quarter worth about $474,993,000. Finally, Beutel Goodman & Co Ltd. lifted its position in Becton, Dickinson and Company by 9.0% during the 3rd quarter. Beutel Goodman & Co Ltd. now owns 1,835,571 shares of the medical instruments supplier’s stock worth $328,567,000 after buying an additional 150,931 shares in the last quarter. Institutional investors and hedge funds own 86.97% of the company’s stock.

Becton, Dickinson and Company Company Profile

(Get Free Report)

Becton, Dickinson and Company, commonly known as BD, is a global medical technology company that develops, manufactures and sells a broad range of products used by healthcare providers, clinical laboratories, pharmaceutical companies and patients. Its offerings support medication delivery, diagnostics, infection prevention, surgical care and other clinical procedures.

BD’s products include needles, syringes, injection devices, intravenous administration systems, medication-management technologies, specimen-collection products, diagnostic systems and laboratory instruments.